151,610 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Acquired by Two Sigma Advisers LP

Two Sigma Advisers LP bought a new stake in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 151,610 shares of the company's stock, valued at approximately $484,000. Two Sigma Advisers LP owned approximately 0.22% of Perspective Therapeutics as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in CATX. Millennium Management LLC acquired a new stake in Perspective Therapeutics in the fourth quarter valued at approximately $4,132,000. Octagon Capital Advisors LP raised its holdings in Perspective Therapeutics by 62.1% during the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company's stock worth $7,352,000 after purchasing an additional 882,528 shares in the last quarter. Affinity Asset Advisors LLC raised its holdings in Perspective Therapeutics by 160.0% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company's stock worth $4,147,000 after purchasing an additional 800,000 shares in the last quarter. Two Sigma Investments LP acquired a new stake in Perspective Therapeutics during the fourth quarter worth approximately $2,075,000. Finally, Walleye Capital LLC raised its holdings in Perspective Therapeutics by 2,526.2% during the fourth quarter. Walleye Capital LLC now owns 475,792 shares of the company's stock worth $1,518,000 after purchasing an additional 457,675 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company's stock.

Insider Buying and Selling at Perspective Therapeutics

In related news, Director Robert F. Williamson III acquired 22,192 shares of the company's stock in a transaction dated Friday, March 28th. The stock was bought at an average price of $2.27 per share, with a total value of $50,375.84. Following the purchase, the director now directly owns 70,837 shares in the company, valued at $160,799.99. The trade was a 45.62% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Juan Graham acquired 33,333 shares of the company's stock in a transaction dated Friday, March 28th. The shares were bought at an average cost of $2.25 per share, with a total value of $74,999.25. Following the purchase, the chief financial officer now owns 35,354 shares in the company, valued at approximately $79,546.50. The trade was a 1,649.33% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 115,696 shares of company stock worth $256,344. Corporate insiders own 3.72% of the company's stock.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock traded up $0.20 on Friday, hitting $3.32. The company's stock had a trading volume of 1,404,539 shares, compared to its average volume of 1,079,388. Perspective Therapeutics, Inc. has a 52-week low of $1.60 and a 52-week high of $16.55. The firm has a fifty day moving average price of $2.33 and a 200-day moving average price of $2.87.

Wall Street Analysts Forecast Growth

CATX has been the topic of a number of research analyst reports. Wedbush reissued an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, May 13th. Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Thursday, March 6th. Royal Bank of Canada raised shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and boosted their price objective for the company from $15.00 to $16.00 in a research note on Tuesday, June 3rd. Truist Financial dropped their price objective on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Finally, Brookline Capital Management raised shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Monday, March 10th. One analyst has rated the stock with a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $12.63.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.